Results 191 to 200 of about 2,461 (207)
Some of the next articles are maybe not open access.
Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes
Journal of Cataract and Refractive Surgery, 2004To evaluate the effect of brimonidine tartrate 0.15% ophthalmic solution (Alphagan P) on pupil diameter in eyes of healthy adults under different luminance conditions.Center for Refractive Surgery, Ophthalmology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA.Using a Colvard pupillometer, the pupil diameter was ...
John E, Thordsen +3 more
openaire +2 more sources
Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane.
Die Pharmazie, 2011Various efforts have been made to improve the bioavailability and to prolong the residence time of eye drops. Drug loaded polymeric nanoparticles offer several favorable biological properties. Thus, brimonidine tartrate (BT) loaded chitosan (CS) nanoparticles were prepared by inducing the ionic gelation upon addition of sodium tripolyphosphate (TPP ...
Shinde, U. A., Singh, K. H.
openaire +2 more sources
Brimonidine tartrate: a one-month dose response study.
Ophthalmology, 1997Brimonidine tartrate is a relatively selective alpha2-agonist that effectively reduces mean intraocular pressure (IOP) and the incidence of IOP spikes after laser trabeculoplasty. The authors were interested in evaluating the dose response of brimonidine when applied topically for a longer duration in patients with elevated IOPs.The authors conducted a
R J, Derick +8 more
openaire +1 more source
Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea
Expert Review of Clinical Pharmacology, 2014Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The goal of this article is to discuss
Lana X, Tong, Angela Yen, Moore
openaire +2 more sources
Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats
Veterinary Anaesthesia and Analgesia, 2017To determine the effects of brimonidine tartrate ophthalmic solution on sedation, heart rate (HR), respiratory frequency (fR), rectal temperature (RT) and noninvasive mean arterial pressure (MAP) in healthy cats.Randomized, blinded crossover study, with 1 week washout between treatments.Six healthy purpose-bred cats.Brimonidine tartrate ophthalmic ...
Niwako, Ogata +8 more
openaire +2 more sources
Charles Bonnet Syndrome Precipitated by Brimonidine Tartrate
Journal of Medical OptometryCharles Bonnet Syndrome (CBS) induced by brimonidine tartrate ophthalmic solution has rarely been reported. CBS is a condition characterized by visual hallucinations in patients with vision loss and clear cognition. This condition is more prevalent in the elderly population, between the ages of 75 and 84 years old.
openaire +1 more source
Design of ocular inserts of brimonidine tartrate by response surface methodology
Journal of Drug Delivery Science and Technology, 2007Reservoir-type ocular inserts of brimonidine tartrate have been formulated by solvent casting technique for once a day administration. The drug-loaded core film was produced by casting a hydroalcoholic solution of hydroxyl propyl methyl cellulose (HPMC) (5% w/v) and glycerin (40% w/w).
H.N. Shivakumar +4 more
openaire +1 more source
Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops
Contact Dermatitis, 2021Napolitano, Maddalena +4 more
openaire +4 more sources